Conditions:  Metastatic Thyroid Gland Carcinoma;  Poorly Differentiated Thyroid Gland Carcinoma;  Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v8;  Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8;  Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8;  Thyroid Gland Anaplastic Carcinoma;  Unresectable Thyroid Gland Carcinoma
Interventions: Â Drug:Â Atezolizumab; Â Biological:Â Bevacizumab; Â Drug:Â Cobimetinib; Â Drug:Â Nab-paclitaxel; Â Drug:Â Paclitaxel; Â Drug:Â Vemurafenib
Sponsors:  M.D. Anderson Cancer Center;  National Cancer Institute (NCI)
**RECRUITING NOW**
Interventions: Â Drug:Â Atezolizumab; Â Biological:Â Bevacizumab; Â Drug:Â Cobimetinib; Â Drug:Â Nab-paclitaxel; Â Drug:Â Paclitaxel; Â Drug:Â Vemurafenib
Sponsors:  M.D. Anderson Cancer Center;  National Cancer Institute (NCI)
**RECRUITING NOW**
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
